Deregulation and More Efficient New Drug Approval Process set to Attract Foreign Investment in the Japanese Pharmaceutical Industry
NEW YORK, LONDON, BERLIN, and PARIS, June 3, 2013 /PRNewswire/ –
Japan’s pharmaceutical industry
is the second largest in the world, worth $89
billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005
to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%. A new report on the
Japanese Pharmaceutical Market
talks about how deregulation and efficient new
drug approval process will attract foreign investment and improve the competitiveness of
Growth of the domestic pharmaceutical industry has recently been hampered by biennial
drug price reductions, which are expected to continue as the government attempts to cut
healthcare expenditure. Price reviews are also constrained by a national health budget,
which limits the increase of drug prices. In addition, the gradual increase in market
share and competition from generics has depressed market value and will continue to do so
as government policy promotes their use.
However, easing of regulatory guidelines, an aging population and a strong product
pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although
the increasing market share of generics may dampen market value, this represents a great
deal of opportunity for generic manufacturers.
Historically, the Japanese pharmaceutical market has favored domestic companies.
However, since the 1990s, deregulation has promoted investment from abroad and increased
the presence of foreign firms.
To view the detailed table of contents of this report kindly click – Deregulation and
More Efficient New Drug Approval Process Set To Attract Foreign Investment In The Japanese
or copy and paste the following link in your
Scope of the Report
- The report assesses characteristics of the Japanese pharmaceutical market, detailing recent regulatory changes, supply chain and competitive landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy. - A macroeconomic analysis of Japan, focusing on key economic parameters such as Gross Domestic Product (GDP), inflation and unemployment. The implications of the global financial crisis in 2008 and natural disaster in 2011 are considered. - The changing demographic landscape and implications on health economics and policy-making. - The industry characteristics section presents an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan. Notable changes that have occurred over recent years, in an attempt to improve the regulatory system and reduce drug review times, are highlighted. - The report then analyzes the competitive landscape in Japan, including the major domestic companies and M&A. The discussed regulatory reforms and cooperation between government and industry have improved the international competitiveness of Japan's pharmaceutical market. Coupled with a number of mergers, the industry now consists of well-known multinationals. The competitive landscape section confirms the top five Japanese pharmaceutical companies by revenue, according to GBI Research data. - The report concludes by providing an overview of the drivers and barriers currently facing the Japanese pharmaceutical industry.
Reasons to buy
- Primarily, the report will allow clients to gain a strong understanding of the economic and healthcare challenges facing Japan. - In addition, the report will assist in identifying opportunities within Japan's pharmaceutical market, including: - Potential for market growth - A number of factors could provide strong potential for sales growth in the Japanese pharmaceutical market. Examples include the world leading life expectancy and associated increase in lifestyle diseases, and government initiatives to prevent such diseases, which provides opportunities for healthcare and pharmaceutical companies, who often carry out the work. - The report provides a source of information covering Japan's regulatory landscape, and importantly, recent deregulation, to help identify the reasons Japan has become an attractive market for big pharma. - The report will provide new market entrants with a comprehensive overview of the leading Japanese pharmaceutical companies, and the specific therapeutic indications they are currently targeting. - Overall, allowing clients to determine whether the Japanese pharmaceutical market will provide them with commercially viable opportunities for growth.
Other Latest Pharma Market research reports
Global Medical Nutrition Market 2012-2016
Global Proteomics Market 2012-2016
Global Vascular Stents Market 2012-2016
Global Atherectomy and Thrombectomy Devices Market 2012-2016
Reportstack.com is one of the leading distributors of market research reports
[http://www.reportstack.com ] in the world today. Reportstack.com provides access to over
50,000 company profiles [http://www.reportstack.com ] and their strategic information like
SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new
product launches. Reportstack.com is also a leader in the field of Pharma partnership
deals and competitor analysis
and Medical Devices Research Reports
Contact Reportstack.com: Nathan Gold Phone: +1-888-789-6604 Email: Info@reportstack.com http://www.reportstack.com Twitter [http://twitter.com/reportstack ]